FTC Approves Final Order Settling Charges that Novartis AG's Proposed Acquisition of Fougera Holdings, Inc. was Anticompetitive

Share This Page

For Your Information


Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG's proposed acquisition of Fougera Holdings, Inc. was anticompetitive in the markets for the marketing rights to four topical skin care medications. The final order resolving the charges preserves competition in the markets by requiring Novartis, a drug supplier, to end a marketing agreement that allows it to sell three of the products and return the rights to the fourth product to its manufacturer.

The Commission vote approving the final order was 5-0. (FTC File No. 121-0144, Docket No. C-4364; the staff contact is Christine Tasso, Bureau of Competition, 202-326-2232; see press release dated July 16, 2012.)

The Federal Trade Commission works for consumers to prevent fraudulent, deceptive, and unfair business practices and to provide information to help spot, stop, and avoid them. To file a complaint in English or Spanish, visit the FTC's online Complaint Assistant or call 1-877-FTC-HELP (1-877-382-4357). The FTC enters complaints into Consumer Sentinel, a secure, online database available to more than 2,000 civil and criminal law enforcement agencies in the U.S. and abroad. The FTC’s website provides free information on a variety of consumer topics.  Like the FTC on Facebook, follow us on Twitter, and subscribe to press releases for the latest FTC news and resources.

Contact Information

Office of Public Affairs